BEIJING, April 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-basedvaccine manufacturer, announced today it filed its annual report on Form 20-F for the fiscal year ended December 31, 2009 with the Securities and Exchange Commission on April 16, 2010. The annual
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.
For further information, please contact: Sinovac Biotech Ltd. Helen G. Yang Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: firstname.lastname@example.org Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: email@example.com firstname.lastname@example.org Media Janine McCargo The Ruth Group Tel: +1-656-536-7033 Email: email@example.com
SOURCE Sinovac Biotech Ltd.
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All